TEVA PHARMACEUTICALS USA, INC.

Use of Section viii statements in pharmaceutical labeling. FDAs approval of over-the-counter naloxone nasal spray. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and legislation to reform pharmacy benefit managers. Patent reform legislation. Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA).

A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37).